Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Morton

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
European Urology Focus|August 25, 2021
Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic ImplicationsArsalan Tariq, Amy E McCart Reed, Andrew Morton, et al.
Brain : a Journal of Neurology|December 18, 2014
Predicting novel histopathological microlesions in human epileptic brain through transcriptional clusteringFabien Dachet, Shruti Bagla, Gal Keren-Aviram, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 9, 2020
<sup>68</sup>Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is <sup>68</sup>Ga-PSMA PET/CT guided biopsy the future?Peter Donato, Andrew Morton, John Yaxley, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 12, 2020
Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancerMatthew J Roberts, Andrew Morton, Peter Donato, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 23, 2020
<sup>68</sup>Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancerMatthew J Roberts, Andrew Morton, Peter Donato, et al.
Clinical Genitourinary Cancer|November 28, 2022
Modern Active Surveillance in Prostate Cancer: A Narrative ReviewTrent A Pattenden, Dhanika Samaranayke, Andrew Morton, et al.
BJU International|September 11, 2023
Barriers and enablers of active surveillance for prostate cancer: a qualitive study of cliniciansTrent A Pattenden, Isaac A Thangasamy, Wee Loon Ong, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 17, 2022
Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomyMatthew J Roberts, Andrew Morton, Nathan Papa, et al.
Oncotarget|July 10, 2018
Cancer-predicting transcriptomic and epigenetic signatures revealed for ulcerative colitis in patient-derived epithelial organoidsSamaneh K Sarvestani, Steven A Signs, Veronique Lefebvre, et al.
Nature Communications|September 25, 2025
MRAP2 modifies the signaling and oligomerization state of the melanocortin-4 receptorIqra Sohail, Suli-Anne Laurin, Gunnar Kleinau, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
European Urology Focus|August 25, 2021
Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic ImplicationsArsalan Tariq, Amy E McCart Reed, Andrew Morton, et al.
Brain : a Journal of Neurology|December 18, 2014
Predicting novel histopathological microlesions in human epileptic brain through transcriptional clusteringFabien Dachet, Shruti Bagla, Gal Keren-Aviram, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 9, 2020
<sup>68</sup>Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is <sup>68</sup>Ga-PSMA PET/CT guided biopsy the future?Peter Donato, Andrew Morton, John Yaxley, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 12, 2020
Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancerMatthew J Roberts, Andrew Morton, Peter Donato, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 23, 2020
<sup>68</sup>Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancerMatthew J Roberts, Andrew Morton, Peter Donato, et al.
Clinical Genitourinary Cancer|November 28, 2022
Modern Active Surveillance in Prostate Cancer: A Narrative ReviewTrent A Pattenden, Dhanika Samaranayke, Andrew Morton, et al.
BJU International|September 11, 2023
Barriers and enablers of active surveillance for prostate cancer: a qualitive study of cliniciansTrent A Pattenden, Isaac A Thangasamy, Wee Loon Ong, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 17, 2022
Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomyMatthew J Roberts, Andrew Morton, Nathan Papa, et al.
Oncotarget|July 10, 2018
Cancer-predicting transcriptomic and epigenetic signatures revealed for ulcerative colitis in patient-derived epithelial organoidsSamaneh K Sarvestani, Steven A Signs, Veronique Lefebvre, et al.
Nature Communications|September 25, 2025
MRAP2 modifies the signaling and oligomerization state of the melanocortin-4 receptorIqra Sohail, Suli-Anne Laurin, Gunnar Kleinau, et al.
Pageof 5